New combo attack on tough breast cancer

NCT ID NCT05748834

Recruiting now Disease control Sponsor: SCRI Development Innovations, LLC Source: ClinicalTrials.gov ↗

Summary

This study is testing whether combining two drugs, tucatinib and Doxil, is safe and effective for treating advanced HER2-positive breast cancer that has spread or returned after prior treatment. It will involve about 36 patients who have already had at least one other HER2-targeted therapy. The main goal is to see if the combination shrinks tumors and to carefully monitor for side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Alliance Cancer Specialists
RECRUITING

Bensalem, Pennsylvania, 19020, United States

Contact
Blue Ridge Cancer Care (Oncology & Hematology Assoc of SW Virginia, Inc)
RECRUITING

Salem, Virginia, 24153, United States

Contact
Maryland Oncology Hematology
RECRUITING

Columbia, Maryland, 21044, United States

Contact
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States

Contact
Tennessee Oncology
ACTIVE_NOT_RECRUITING

Nashville, Tennessee, 37203, United States
Texas Oncology- DFW
RECRUITING

Dallas, Texas, 75246, United States

Contact
Texas Oncology- San Antonio
RECRUITING

San Antonio, Texas, 78240, United States

Contact
Virginia Oncology Associates
RECRUITING

Norfolk, Virginia, 23502, United States

Contact

Conditions

Explore the condition pages connected to this study.

BREAST CANCER